External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Overall increase in competition and persisting price erosion in US market (68% revenue in the US) and higher frequency of USFDA inspection may lead to more surprise in upcoming quarters</li><li>Therefore, we recommend HOLD rating on the stock with Target Price of Rs 740/share.</li><li>Aurobindo Pharma (ARBP) Q2FY22 consolidated revenue (Ex-Natrol) degrew by -2.1% YoY, as ARV (-71%, YoY) and API (-5%, YoY) dragged the topline.</li></ul><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Overall increase in competition and persisting price erosion in US market (68% revenue in the US) and higher frequency of USFDA inspection may lead to more surprise in upcoming quartersTherefore, we recommend HOLD rating on the stock with Target Price of Rs 740/share.Aurobindo Pharma (ARBP) Q2FY22 consolidated revenue (Ex-Natrol) degrew by -2.1% YoY, as ARV (-71%, YoY) and API (-5%, YoY) dragged the topline.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma: US Market Outshines Despite Weakness in the Industry